Shares of Moderna jumped by a staggering 10.53% to $144.81 at 14:56 EST on Monday, following last session’s downward trend. NASDAQ Composite is rising 0.31% to $13,585.50, after four consecutive sessions in a row of gains. This seems, at the moment, a somewhat positive trend exchanging session today.
Moderna’s last close was $131.02, 23.26% below its 52-week high of $178.50.
News about Moderna today
Moderna developing booster shot against strain first identified in South Africa. According to today’s article on The Wall Street Journal, "Even with the decrease, Moderna said, the vaccine-induced antibody response against the B.1.35 variant remained above levels that are expected to be protective. "
Moderna plans to test booster shot against South Africa strain. According to today’s article on Bloomberg Quint, "In lab tests conducted with the National Institute of Allergy and Infectious Diseases, Moderna says its vaccine produced six-fold lower levels of neutralizing antibodies against the South Africa variant called B.1.351 than it did against the original Covid-19 strain.", "Even with the lower antibody levels, its existing vaccine should still protect against people who are exposed to the South Africa strain, Moderna said in a statement. "
Moderna: lab study confirms its Covid-19 vaccine still protects against new variants. According to today’s article on MarketWatch, "Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. "
Moderna: study confirms Covid-19 vaccine protects against new variants. According to today’s article on MarketWatch, "Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. "
Moderna climbs 12% after saying its coronavirus vaccine likely protects against new strains found in the UK and South Africa. According to today’s article on Business Insider, "Out of an abundance of caution," the biotech company will begin testing a booster shot tailored to protect people against the South African variant, according to Moderna CEO Stéphane Bancel.", "In a press release, Moderna stated that its mRNA-1273 COVID-19 vaccine can probably protect people against variants of the disease first found in South Africa and the UK. "
Moderna’s sales growth is 1989.6% for the current quarter and 19117.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s last day, last week, and last month’s average volatility was a negative 1.50%, a positive 0.22%, and a negative 0.28%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 5.41%, 5.61%, and 7.99%, respectively.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $144.81 at 14:56 EST, way below its 52-week high of $178.50 and way higher than its 52-week low of $17.91.
Moderna’s Moving Average
Moderna’s value is way higher than its 50-day moving average of $130.81 and way above its 200-day moving average of $90.07.
Previous days news about Moderna
Moderna lags in WHO vaccine drive as Chinese shots near approval. According to Bloomberg Quint on Friday, 22 January, "This is despite the fact that Moderna is one of 11 vaccine candidates that received funding from the WHO-backed Coalition for Epidemic Preparedness, though the $1 million provided paled in comparison to the hundreds of millions the company received from the U.S. government’s Operation Warp Speed.", "The company is in dialogue with the WHO and is committed to a successful outcome, a Moderna spokesman said in an emailed statement to Bloomberg News, without giving further details."
CDC finds one in 400,000 had anaphylaxis after Moderna shot. According to Bloomberg Quint on Friday, 22 January, "The CDC’s Nordlund said that as of Jan. 19, there have been 15 cases of anaphylaxis with the Moderna shot and 45 with the Pfizer shot, rates of 2.1 cases per million doses and 6.2 cases per million doses, respectively. ", "About one in 400,000 recipients of the Moderna Inc. Covid-19 vaccine had a severe allergic reaction to the first shot, according to a study from the U.S. Centers for Disease Control and Prevention released on Friday."